Company intelligence
HealthSeed AG
Swiss healthcare venture studio | EU/USA/MENA market entry, commercialization and AI drug discovery partnerships
About HealthSeed AG
HealthSeed is a Swiss healthcare venture studio helping biotech, medtech, diagnostics, AI drug discovery, and digital-health companies launch and scale across Europe, North America, and MENA. We work with companies that have strong technology, evidence, or early traction, but need the commercial infrastructure to move from validation to adoption, revenue, and international scale. Built by senior healthcare operators, HealthSeed provides integrated support across market-entry strategy, regulatory pathways, reimbursement and HTA, hospital partnerships, real-world evidence, go-to-market execution, pharma business development, investor readiness, and commercial launch. Our core offering is the HealthSeed EU Launchpad: one coordinated programme covering regulatory, reimbursement, hospital partnerships, and commercial launch for companies entering or scaling across European markets. HealthSeed is not a traditional consultancy. We do not sell advice and decks. We embed as an operating partner, assemble specialist teams around each engagement, and align our economics with commercial outcomes. Headquartered in Zurich/Basel, HealthSeed combines Swiss roots with international reach across Europe, North America, MENA, and selected global health innovation ecosystems. HealthSeed — where health innovation grows.
Verified activity
Signals from HealthSeed AG
2 published signals
Presence & Recognition
HealthSeed AG hosted the AI Drug Discovery discussion at the HealthVC Summit in Zurich, exploring how breakthrough science becomes an investable company and reaches patients faster.
Reported by Safia Agueni
Research & Knowledge
HealthSeed AG published the first blinded prospective antibody benchmark for AI drug discovery, featuring 511 submissions from 29 organisations across three tasks published in Nature Biotechnology on 19 August, with 71.5 percent of valid submissions bound the target and a winning design reaching 94.7 picomolar in under a week against a laboratory control of 113 picomolar.
Reported by HealthSeed AG